RSM conducted financial, tax, and payroll due diligence for ProductLife Group during the acquisition of IntiQuan AG

RSM, the 6th largest global advisory and audit network, performed buy-side financial, tax, and payroll due diligence for ProductLife Group, a leading regulatory consulting company for the life sciences industry, during the acquisition of IntiQuan AG, a Swiss consulting firm offering services and solutions for drug development.

A Franco-Swiss task force, under the supervision of Eric Fougedoire, RSM partner, supported ProductLife Group in this acquisition.

Through this operation, RSM’s Corporate Finance division once again demonstrates its financial expertise dedicated to regulatory consulting by supporting leading players in the life sciences sector.

ProductLife Group (PLG),the global leader in digital transformation, regulatory, scientific, and compliance services for the life sciences industry, is pleased to announce the acquisition of IntiQuan AG, a leading Swiss boutique specializing in pharmacometric services for the biopharmaceutical sector.

Founded in Switzerland in 2015 by Dr. Henning Schmidt, IntiQuan quickly established itself as a trusted provider of cutting-edge pharmacometric and statistical modeling and simulation services. This acquisition allows PLG to expand its portfolio of specialized solutions to support biopharmaceutical companies in drug development by adding a key set of competencies aimed at significantly reducing risks, costs, and development timelines, while enhancing patient safety through advanced dose-response analysis and predictive safety profiles.
With the addition of IntiQuan, PLG is now able to offer its clients cutting-edge pharmacometric services, including strategic consulting, pharmacokinetics/pharmacodynamics (PK/PD), population pharmacokinetics (popPK), and biosimulation services. IntiQuan is recognized for its ability to transform complex data into actionable insights across a wide range of therapeutic areas and modalities, from preclinical to phase IV. Its team of scientific experts uses advanced mathematical modeling and simulation techniques to guide clinical study design and analyze and predict trial outcomes.

This acquisition represents a further step in PLG’s strategy to create a fully integrated global platform. With additional expansions planned in the United States and Europe, PLG is on track to become a global leader in providing comprehensive drug development services.

Xavier Duburcq, , CEO of PLG, commented: “We are excited to welcome the IntiQuan team into PLG. Their cutting-edge scientific expertise in pharmacometrics and clinical pharmacology integrates perfectly with our expertise-focused organization. Their in-depth, highly specialized knowledge will enhance the support we offer our clients in their drug development journey. Pharmacometrics and model-based drug development provide regulatory-quality insights that can influence key decision-making and accelerate clinical development, and in some cases, eliminate the need for certain trials.”

Dr. Henning Schmidt, founder of IntiQuan, added: “Joining PLG marks a pivotal moment for IntiQuan. Our teams support IntiQuan’s clients in bringing breakthrough medicines to patients while reducing time-to-market and research and development costs with our combined solutions. We are excited to contribute our unique skills to PLG’s global platform and play a key role in the future of drug development.”

Le Dr Stefan Wetzel, PDG d'IntiQuan, stated: “There is a strong cultural alignment between our organizations, focused on delivering innovative, high-quality, and customer-oriented solutions. Together with our colleagues at PLG, we look forward to supporting our clients with a wider range of complementary solutions, including regulatory services.”

Capitalmind Investec acted as M&A advisor, and Advestra as the legal and tax advisor to the sellers.

DDA & Company and Hoffman & Partner acted as M&A advisors, RSM as the financial and tax advisor, and CMS Von Erlach Partners as the legal advisor for ProductLife Group.

The RSM teamEquipe RSM

The RSM team involved included:

• Financial due diligence: Eric Fougedoire, Jean-Yves Bonvin, Benjamin Gibello
• Tax and payroll due diligence: Daniel Spitz, Weronika Ludwiczak, Mathias Jollien